Summary
A characteristic feature of both Parkinson's disease (idiopathic paralysis agitans) and normal aging is loss of pigmented neurons in the substantia nigra. This has been found to correlate with the accumulation of neuromelanin and with oxidative stress in this brain region, but a clear association between these factors has not been established. Based on our recent demonstration that neuromelanin is a true melanin, containing bound metal ions in situ, we present a general model for its accumulation in vivo and the hypotheses (1) that it has a cytoprotective function in the sequestration of redox-active metal ions under normal conditions but (2) that it has a cytotoxic role in the pathogenesis of Parkinson's disease. Thus, neuromelanin accumulates normally through the autooxidation of catecholamines and serves tightly to bind redox-active metal ions, processes which would accelerate under conditions of intracellular or extracellular oxidative stress. Based on the known properties of melanin, however, neuromelanin also has the potential for exacerbating oxidative stress, eg by generating H2O2 when it is intact or by releasing redox-active metal ions if it loses its integrity; these reactions also would modulate the reactivity of the neuromelanin. By overwhelming intracellular antioxidative defense mechanisms, such a positive-feedback cycle could turn a condition of chronic or repeated oxidative stress in vulnerable neurons into an acute crisis, leading to cellular death. If the cumulative stress in duration and/or degree is severe enough, neuronal depletion could be sufficient to cause Parkinson's disease during life. One possible trigger for this cascade is suggested by the increased nigral iron contents in postmortem parkinsonian brains and the correlation of this disease with urban living where exposure to heavy metal ions is high: the saturation of neuromelanin with redox-active metal ions. Parkinson's disease therefore may be a form of accelerated aging in the substantia nigra associated with environmental toxins in which neuromelanin has a central, active role.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Adams JD, Odunze IN (1991a) Biochemical mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity: could oxidative stress be involved in the brain. Biochem Pharmacol 41: 1099–1105
Adams JD, Odunze IN (1991b) Oxygen free radicals and Parkinson's disease. Free Radic Biol Med 10: 161–169
Barbeau A (1984a) Manganese and extrapyramidal disorders. Neurotoxicology 5: 13–36
Barbeau A (1984b) Etiology of Parkinson's disease: a research strategy. Can J Neurol Sci 11: 24–28
Barden H (1971) The histochemical distribution and localization of copper, iron, neuromelanin and lysosomal enzyme activity in the brain of aging rhesus monkey and the dog. J Neuropathol Exp Neurol 30: 650–667
Barden H (1975) The histochemical relationships and nature of neuromelanin. In: Brody H, Harman D, Ordy JM (eds) Aging, vol 1. Raven Press, New York, pp 79–117
Barden H (1981) The biology and chemistry of neuromelanin. In: Sohal RS (ed) Age pigments. Elsevier/North-Holland Biomedical Press, Amsterdam, pp 155–180
Barden H, Brizzee KR (1987) The histochemistry of lipofuscin and neuromelanin. In: Totaro EA, Glees P, Pisanti FA (eds) Advances in the biosciences, vol 64. Pergamon Press, Oxford, pp 339–392
Bazelon M, Fenichel GM (1967) Studies on neuromelanin I. A melanin system in the human adult brainstem. Neurology 17: 512–519
Ben-Shachar D, Youdim MBH (1990) Selectivity of melanized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction. J Neural Transm [Suppl] 29: 251–258
Ben-Shachar D, Riederer P, Youdim MBH (1991) Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem 57: 1609–1614
Ben-Shachar D, Eshel G, Riederer P, Youdim MBH (1992) Role of iron and iron chelation in dopaminergic-induced neurodegeration: implications for Parkinson's disease. Ann neurol [Suppl] 32: S105-S110
Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415–455
Boettner EA, Wolter JR (1962) Transmission in the ocular media. Invest Opthalmol Vision Res 1: 776–781
Bogerts B (1981) A brainstem atlas of catecholaminergic neurons in man, using melanin as a natural marker. J Comp Neurol 197: 63–80
Bowness JM, Morton RA, Shakir MH, Stubbs AL (1952) Distribution of copper and zinc in mammalian eyes. Occurrence of metals in melanin fractions from eye tissues. Biochem J 51: 521–530
Bruenger FW, Stover BJ, Atherton DR (1967) The incorporation of various metal ions into in vivo- and in vitro-produced melanin. Radiat Res 32: 1–12
Carstam R, Brinck C, Hindemith-Augustsson A, Rorsman H, Rosengren E (1992) The neuromelanin of the human substantia nigra. Biochem Biophys Acta 1097: 152–160
Cohen G (1983) The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. J Neural Transm [Suppl] 19: 89–103
Cohen G (1986) Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. Adv Neurol 45: 119–125
Commoner B, Townsend J, Pake GE (1954) Free radicals in biological materials. Nature 74: 689–691
Connor JR, Menzies SL, St. Martin SM, Musson EJ (1990) Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J Neurosci Res 27: 595–611
Cotzias GC, Papavasiliou PS, Van Woert MH, Sakamato A (1964) Melanogenesis and extrapyramidal diseases. Fed Proc 23: 713–718
Cumings JN (1968) Trace metals in the brain and in Wilson's disease. J Clin Pathol 21: 1–7
D'Amato RJ, Alexander GM, Schwartzman RJ, Kitt CA, Price DL, Snyder SH (1987) Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. Nature 327: 324–326
Das KC, Abramson MB, Katzman R (1978) Neuronal pigments: spectroscopic characterization of human brain melanin. J Neurochem 30: 601–605
Dexter DT, Wells FR, Lees AJ, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52: 1830–1836
Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114: 1953–1975
Dexter DT, Jenner P, Schapira AHV, Marsden CD (1992) Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. Ann Neurol [Suppl] 32: S84-S100
d'Ischia M, Napolitano A, Prota G (1987) Sulphydryl compounds in melanogensis. Part I. Reaction of cysteine and glutathione with 5,6-dihydroxyindoles. Tetrahedron 43: 5351–5356
d'Ischia M, Napolitano A, Prota G (1987) Sulphydryl compounds in melanogensis. Part II. Reactions of cysteine and glutathione with dopachrome. Tetrahedron 43: 5357–5362
Dolman CL, MacLeod PM (1981) Lipofuscin and its relation to aging. Adv Cell Neurobiol 2: 205–247
Earle KM (1968) Studies on Parkinson's disease including X-ray fluorescent spectroscopy of formalin-fixed brain tissue. J Neuropathol Exp Neurol 27: 1–14
Eidelberg D (1992) Positron emmision tomography studies in parkinsonism. Neurol Clin 10(2): 421–433
Elizan TS, Casals J (1983) The viral hypothesis in Parkinsonism. J Neural Transm [Suppl] 19: 75–88
Enochs WS, Nilges MJ, Swartz HM (1993a) A standardized test for the identification and characterization of melanins using electron paramagnetic resonance (EPR) spectroscopy. Pigment Cell Res 6: 91–99
Enochs WS, Nilges MJ, Swartz HM (1993b) Purified human neuromelanin, synthetic dopamine melanin as a potential model pigment, and the normal human substantia nigra: characterization by electron paramagnetic resonance (EPR) spectroscopy. J Neurochem 61: 68–79
Fahn S (1989) The endogenous toxin hypothesis of the etiology of Parkinson's disease and a pilot trial of high-dosage antioxidants in an attempt to slow the progression of the illness. Ann NY Acad Sci 570: 186–196
Fahn S (1992) A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann Neurol [Suppl] 32: S128-S132
Felix CC, Hyde JS, Sarna T, Sealy RC (1978) Melanin photoreactions in aerated media: electron spin resonance evidence for production of superoxide and hydrogen peroxide. Biochem Biophys Res Commun 84: 335–341
Fornstedt B, Rosengren E, Carlsson A (1986) Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, DOPA, and DOPAC in the brains of eight mammalian species. Neuropharmacology 25: 451–454
Fornstedt B, Brun A, Rosengren E, Carlsson A (1989) The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J Neural Transm [P-D Sect] 1: 279–295
Furtado JCS, Mazurek MF (1991) MPTP-induced neurotoxicity and the quest for a preventive therapy for Parkinson's disease. Can J Neurol Sci 18: 77–82
Froncisz W, Sarna T, Hyde JS (1980) Cu2+ probe of metal ion binding sites in melanin using electron paramagnetic resonance spectroscopy I. Synthetic melanins. Arch Biochem Biophys 202: 289–303
Goldsmith JR, Herishanu Y, Abarbanel JM, Weinbaum Z (1990) Clustering of Parkinson's disease points to environmental etiology. Arch Environ Health 45: 88–94
Götz ME, Freyberger A, Riederer P (1990) Oxidative stress: a role in the pathogenesis of Parkinson's disease. J Neural Transm [Suppl] 29: 241–249
Graham DG (1978a) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14: 633–643
Graham DG, Tiffany SM, Bell WR, Gutknecht WF (1978b) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6- hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 14: 644–653
Graham DG (1979) On the origin and significance of neuromelanin. Arch Pathol Lab Med 103: 359–362
Graham DG (1984) Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease. Neurotoxicology 5: 83–96
Greenfield JG, Bosanquet FD (1953) The brain-stem lesions in parkinsonism. J Neurol Neurosurg Psychiatry 16: 213–226
Hall ED (1992) Novel inhibitors of iron-dependent lipid peroxidation for neurodegenerative disorders. Ann Neurol [Suppl] 32: S137-S142
Halliwell B (1981) Free radicals, oxygen toxicity and aging. In: Sohal RS (ed) Age pigments. Elsevier/North-Holland Biomedical Press, Amsterdam, pp 1–62
Halliwell B, Gutteridge JMC (1984) Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 219: 1–14
Halliwell B (1989) Oxidants and the central nervous system: some fundamental questions. Acta Neurol Scand 126: 23–33
Heacock RA, Laidlaw BD (1958) Reduction of adrenochrome with ascorbic acid. Nature 182: 526–527
Heacock RA, Scott BD (1959) The reduction of adrenochrome with thiols. Can J Biochem Physiol 37: 1087–1088
Hill JM, Switzer RC (1984) The regional distribution and cellular localization of iron in the rat brain. Neurosience 11: 595–603
Hintz P, Kalyanaraman B (1986) Metal ion-induced activation of molecular oxygen in pigmented polymers. Biochem Biophys Acta 883: 41–45
Hirosawa K (1968) Electron microscopic studies on pigment granules in the substantia nigra and locus coeruleus of the Japanese monkey (Macaca fuscata yukui). Z Zellforsch 88: 187–203
Hirsch EC, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334: 345–348
Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y (1991) Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 56: 446–451
Hirsch EC (1992) Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease? Ann Neurol [Suppl] 32: S88-S93
Horcicko J, Borovansky J, Duchon J, Prochazkova B (1973) Distribution of zinc and copper in pigmented tissues. Z Physiol Chem 354: 203–204
Hornykiewicz O (1966) Dopamine (3-hydroxytryptamine) and brain function. Pharmacol Rev 18: 925–964
Hornykiewicz O (1973) Parkinson's disease: from brain homogenate to treatment. Fed Proc 32: 183–190
Hornykiewicz O, Kish SJ (1986) Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45: 19–34
Issdorides MR (1971) Neuronal vascular relationships in the zona compact of normal and parkinsonian substantia nigra. Brain Res 25: 289–299
Ito S, Imai Y, Jimbow K, Fujita K (1988) Incorporation of sulfhydryl compounds into melanins in vivo. Biochem Biophys Acta 964: 1–7
Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MBH (1990) Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm [P-D Sect] 2: 327–340
Jellinger K, Kienzl E, Rumpelmair G, Riederer P, Stachelberger H, Ben-Shachar D, Youdim MBH (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J Neurochem 59: 1168–1171
Jenner P (1992) What process causes nigral cell death in Parkinson's disease? Neurol Clin 10: 387–403
Jenner P, Dexter DT, Sian J, Schapira AHV, Marsden CD (1992) Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann Neurol [Suppl] 32: S 82–87
Jimbow K, Quevedo WC, Fitzpatrick TB, Szabo G (1976) Some aspects of melanin biology: 1950–1975. J Invest Dermatol 67: 72–89
Kalyanaraman B, Felix CC, Sealy RC (1984) Peroxidatic oxidation of catecholamines: a kinetic electron spin resonance investigation using the spin stabilization approach. J Biol Chem 259: 7584–7589
Kalyanaraman B, Premovic PI, Sealy RC (1987) Semiquinone anion radicals from addition of amino acids, peptides, and proteins to quinones from oxidation of catechols and catecholamines. J Biol Chem 262: 1080–1087
Kollias N, Sayre RM, Chedekel LZ, Chedekel MR (1991) Photoprotection by melanin. J Photochem Photobiol B Biol 9: 135–160
Korytowski W, Hintz P, Sealy RC, Kalyanaraman B (1985) Mechanism of dismutation of superoxide produced during autooxidation of melanin pigments. Biochem Biophys Res 131: 659–665
Korytowski W, Pilas B, Sarna T, Kalyanarman B (1987) Photoinduced generation of hydrogen peroxide and hydroxyl radicals in melanins. Photochem Photobiol 45: 185–190
Korytowski W, Sarna T (1990) Bleaching of melanin pigments. J Biol Chem 265: 12410–12416
Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980
Langston JW, Irwin I, Ricaurte GA (1987) Neurotoxins, parkinsonism, and Parkinson's disease. Pharmacol Ther 32: 19–49
Langston JW (1989) Current theories on the cause of Parkinson's disease. J Neurol Neurosurg Psychiatry [Spec Suppl]: 13–17
Larsen NA, Pakkenberg H, Damsgaard E, Heydorn K (1979) Topographical distribution of arsenic, manganese, and selenium in the human brain. J Neurol Sci 42: 407–416
Larsson B, Tjalve H (1978) Studies on the melanin-affinity of metal ions. Acta Physiol Scand 104: 479–484
Lillie RD, Yamada H (1960) Histochemical studies on the neuromelanins. Okajimas Folia Anatom Japon 36: 155–163
Lindquist NG, Larsson BS, Lyden-Sokolowski A (1987) Neuromelanin and its possible protective and destructive properties. Pigment Cell Res 1: 133–136
Lukiewicz S (1972) The biological role of melanin I. New concepts and methodical approaches. Folia Histochem Cytochem 10: 93–108
Lyden A, Larsson BS, Lindquist NG (1984) Melanin affinity of manganese. Acta Pharmacol Toxicol 55: 133–138
Maeda T, Wegmann R (1969) Infrared spectrometry of locus coeruleus and substantia nigra pigments in human brain. Brain Res 14: 673–681
Mann DMA, Yates PO (1974) Lipoprotein pigments — Their relationship to aging in the human nervous system II. The melanin content of pigmented nerve cells. Brain 97: 489–498
Mann DMA, Yates PO, Barton CM (1977) Neuromelanin and RNA in cells of substantia nigra. J Neuropathol Exp Neurol 36: 379–383
Mann DMA, Yates PO (1979) The effects of ageing on the pigmented nerve cells of the human locus caeruleus and substantia nigra. Acta Neuropathol 47: 93–97
Mann DMA, Yates PO (1983) Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech Age Dev 21: 193–203
Marsden CD (1961) Pigmentation in the nucleus substantia nigrae of mammals. J Anat 95: 256–261
Marsden CD (1969) Brain melanin. In: Wolman M (ed) Pigments in pathology. Academic Press, New York, pp 395–420
Marttila RJ, Rinne UK (1989) Oxygen toxicity protecting enzymes in aging and Parkinson's disease. In: Calne DB (ed) Parkinsonism and aging. Raven Press, New York, pp 89–95
Mason HS, Ingram DJE, Allen B (1960) The free radical property of melanins. Arch Biochem Biophys 86: 225–230
Mattock C, Marcot M, Stern G (1988) Could Parkinson's disease follow intrauterine influenza? A speculative hypothesis. J Neurol Neurosurg Psychiatry 51: 753–756
Mikulski T (1970) Electron spin resonance (ESR) and infrared spectra of the eye melanin and of the pigment in substantia nigra. Acta Physiol Pol 21: 175–180
Moses HL, Ganote CE, Beaver DL, Schuffman SS (1966) Light and electron microscopic studies of pigment in human and rhesus monkey substantia nigra and locus coeruleus. Anat Rec 155: 167–184
Nordgren L, Rorsman H, Rosengren AM, Rosengren E (1971) Dopa and dopamine in the pigment of substantia nigra. Experientia 27: 1178–1179
Okazaki M, Kuwata K, Miki Y, Shiga S, Shiga T (1985) Electron spin relaxation of synthetic melanin and melanin-containing human tissue as studied by electron spin echo and electron spin resonance. Arch Biochem Biophys 242: 197–205
Okun MR, Donnellan B, Lever WF (1971) Peroxidase-dependent oxidation of tyrosine or dopa to melanin in neurons. Histochemie 25: 289–296
Olanow CW (1990) Oxidation reactions in Parkinson's disease. Neurology [Suppl 3] 40: 32–37
Olanow CW (1992) Magnetic resonance imaging in parkinsonism. Neurol Clin 10: 405–420
Olanow CW (1992) An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol [Suppl] 32: S2-S9
Pakkenberg H, Brody H (1965) The number of nerve cells in the substantia nigra in paralysis agitans. Acta Neuropathol 5: 320–324
Parkinson TF, Millikan LE, Anderson DF (1979) Manganese, copper and zinc concentrations in human skin lesions. Int J Appl Radiat Isotopes 30: 411–415
Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328: 176–183
Pathak MA, Jimbow K, Szabo G, Fitzpatrick TB (1976) Sunlight and melanin pigmentation. In: Smith KC (ed) Photochemical and photobiological reviews, vol 1. Plenum Press, New York, pp 211–239
Perl DP, Good PF (1992) Comparitive techniques for determining cellular iron distribution in brain tissues. Ann Neurol [Suppl] 32: S76-S81
Pilas B, Sarna T, Kalyanaraman B, Swartz HM (1988) The effect of melanin on iron associated decomposition of hydrogen peroxide. Free Radic Biol Med 4: 285–293
Poirier J, Kogan S, Gauthier S (1991) Environment, genetics and idiopathic Parkinson's disease. Can J Neurol Sci 18: 70–76
Potts AM, Au PC (1976) The affinity of melanin for inorganic ions. Exp Eye Res 22: 487–491
Riederer P, Sofic E, Rausch W-D, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH, (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515–520
Riederer P, Dirr A, Goetz M, Sofic E, Jellinger K, Youdim MBH (1992) Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann Neurol [Suppl] 32: S101-S104
Rosengren E, Linder-Eliasson E, Carlsson A (1985) Detection of 5-S-cysteinyldopamine in human brain. J Neural Transm 63: 247–253
Rumyantseva GY, Weiner LM, Molin YN, Budker VG (1979) Permeation of liposome membrane by superoxide radical. FEBS Lett 108: 477–480
Sarna T, Hyde JS, Swartz HM (1976) Ion-exchange in melanin. An electron spin resonance study with lanthanide probes. Science 192: 1132–1134
Sarna T, Swartz HM (1978) Identification and characterization of melanin in tissues and body fluids. Folia Histochem Cytochem 16: 275–286
Sarna T, Duleba A, Korytowski W, Swartz H (1980a) Interaction of melanin with oxygen. Arch Biochem Biophys 200: 140–148
Sarna T, Froncisz W, Hyde JS (1980b) Cu2+ probe of metal binding sites in melanin using electron paramagenetic resonance spectroscopy II. Natural melanin. Arch Biochem Biophys 202: 304–313
Sarna T, Korytowski W, Pasenkiewicz-Gierula M, Gudowska E (1981) Ion-exchange studies in melanins. In: Seiji M (ed) Pigment cell 1981: phenotypic expression in pigment cells. University of Tokyo Press, Tokyo, pp 23–29
Sarna T, Sealy RC (1984) Photoinduced oxygen consumption in melanin systems. Action specta and quantum yields for eumelanin and synthetic melanin. Photochem Photobiol 39: 69–74
Sarna T, Pilas B, Land EJ, Truscott TG (1986) Interaction of radicals from water radiolysis with melanin. Biochim Biophys Acta 883: 162–167
Sarna T, Swartz HM (1993) Interactions of melanin with oxygen (and related species). In: Scott G (ed) Atmospheric oxidation and antioxidants, vol III. Elsevier, Amsterdam, pp 129–169
Sarna T (1992) Properties and function of the ocular melanin: a photobiophysical view. J Photochem Photobiol B 12: 215–258
Sealy RC, Felix CC, Hyde JS, Swartz HM (1980) Structure and reactivity of melanins: influence of free radicals and metal ions. In: Prior WA (ed) Free radicals in biology, vol 4. Academic Press, New York, pp 209–259
Sealy RC, Puzyna W, Kalyanaraman B, Felix CC (1984) Identification by electron paramagnetic spectroscopy of free radicals produced during autooxidative melanogenesis. Biochem Biophys Acta 800: 269–276
Shoulson I (1992) Neuroprotective clinical strategies for Parkinson's disease. Ann Neurol [Suppl] 32: S143-S145
Singer TP, Castagnoli N, Ramsay RR, Trevor AJ (1987) Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 49: 1–8
Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MBH (1988) Increased iron (III) and total iron content in postmortem substantia nigra of parkinsonian brain. J Neural Transm 74: 199–205
Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MBH (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 56: 978–982
Stein WD (1955) Chemical composition of the melanin granule and its relation to the mitochondrion. Nature 175: 256–257
Stern GM (ed) (1990) Parkinson's disease. Johns Hopkins University Press, Baltimore
Swartz HM, Sarna T, Zecca L (1992) Modulation by neuromelanin of the availability and reactivity of metal ions. Ann Neurol [Suppl] 32: S69-S75
Szekeres L (1975) Fine structure and X-ray microanalysis of melanosomes in pigmented nevi and melanomas. Arch Derm Forsch 252: 291–304
Tanner CM (1989) The role of environmental toxins in the etiology of Parkinson's disease. Trends Neurol Sci 12: 49–54
Tanner CM (1992) Epidemiology of Parkinson's disease. Neurol Clin 10(2): 317–329
Tse DCS, McCreery RL, Adams RN (1976) Potential oxidative pathways of brain catecholamines. J Med Chem 19: 37–40
Uitti RJ, Rajput AH, Rozdilsky B, Bickis M, Wollin T, Yuen WK (1989) Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains. Can J Neurol Sci 16: 310–314
Van Woert MH, Prasad KN, Borg DC (1967) Spectroscopic studies of substantia nigra pigment in human subjects. J Neurochem 14: 707–716
Van Woert MH, Ambani LM (1974) Biochemistry of neuromelanin. Adv Neurol 5: 215–223
Vistnes AI, Henricksen T, Nicolaissen B, Armstrong D (1983) Free radicals and aging. Electron spin resonance studies on neuronal lipopigments and cells grown in vitro. Mech Age Dev 22: 335–345
Warren PJ, Earl CJ, Thompson RHS (1960) The distribution of copper in human brain. Brain 83: 709–717
White LP (1958) Melanin: a naturally occurring cation exchange material. Nature 182: 1427–1428
Wolters EC, Calne DB (1989) Is Parkinson's disease related to aging? In: Calne DB (ed) Parkinsonism and aging. Raven Press, New York, pp 125–132
Youdim MBH, Ben-Shachar D, Riederer P (1989) Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin-induced neurodegeneration? Acta Neurol Scand 126: 47–54
Zecca L, Mecacci C, Seraglia R, Parati E (1992) The chemical characterization of melanin contained in substantia nigra of human brain. Biochem Biophys Acta 1138: 6–10
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Enochs, W.S., Sarna, T., Zecca, L. et al. The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: A hypothesis. J Neural Transm Gen Sect 7, 83–100 (1994). https://doi.org/10.1007/BF02260963
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02260963